June 2, 2025 11:11 AM EDT

Regeneron makes $80M obesity deal with Hansoh

Elizabeth Cairns

Senior biopharma journalist

Regeneron has followed in Merck’s footsteps by licensing an obesity candidate from the China-based biotech Hansoh Pharma. But Regeneron got a much more advanced candidate …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

Regeneron makes $80M obesity deal with Hansoh

Elizabeth Cairns

Senior biopharma journalist

Sign up to read this article for free.

COO / Head of Operations (Stealth Portfolio Company)‬ ‭

Autonomy Bio Inc.

San Francisco, CA 94107, USA

Pharma companies rush in to buy what they hope will rival Keytruda

New CBER chief Prasad promises to 'rapidly' push even small advances for rare disease drugs

At ASCO, cell therapies for deadly form of brain cancer make early strides

BioNTech presents impressive early data for PD-L1xVEGF in mesothelioma

Agenus quickly exits CDMO business by selling assets to Zydus for $75M upfront

Cytiva and EurekaBio form strategic partnership to advance lentiviral vector manufacturing for cell and gene therapy ...

Re­gen­eron makes $80M obe­si­ty deal with Han­soh

Senior biopharma journalist

Sign up to read this article for free.

Autonomy Bio Inc.

San Francisco, CA 94107, USA

Regeneron makes $80M obesity deal with Hansoh